The Effect of Post-voiding Reisdual Urine on Non-muscle Invasive Bladder Cancer Recurrence and Progression
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 500
- Locations
- 6
- Primary Endpoint
- Recurrence
Study Overview
Brief Summary
Although transurethral resection is the main treatment option for stage Ta and T1 disease, relapse is frequently detected. Tumor number, tumor size, T stage, presence of in situ carcinoma and tumor grade are risk factors for recurrence. The relationship between post voiding residual urine volume and bladder tumor recurrence and progression has not been clearly established. The investigators aimed to examine the effect of high post voiding residual urine volume on recurrence and progression based on the hypothesis that tumor cells circulating in the bladder may increase with excess residual urine.
Detailed Description
Although transurethral resection is the main treatment option for stage Ta and T1 disease, relapse is frequently detected. Tumor number, tumor size, T stage, presence of in situ carcinoma and tumor grade are risk factors for recurrence. The relationship between post voiding residual urine volume and bladder tumor recurrence and progression has not been clearly established. Participants who underwent transurethral resection for bladder tumor will be included in the study. The investigators aimed to examine the effect of high post voiding residual urine volume on recurrence and progression based on the hypothesis that tumor cells circulating in the bladder may increase with excess residual urine.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients with transitional cell non-muscle invasive bladder cancer (NMIBC) pathology
- •Patients with a diagnosis of Bladder cancer (NMIBC)
- •Patients undergoing transurethral resection for bladder cancer (NMIBC)
- •≥18 years old patients
Exclusion Criteria
- •Non-transitional cell bladder cancers
- •Patients with muscle-invasive bladder cancer pathology
- •<18 years old patients
Arms & Interventions
Low residual volume
Bladder tumor patients with low residual volume
High residual volume
Bladder tumor patients with high residual volume
Outcomes
Primary Outcomes
Recurrence
Time Frame: 1 year
Non-muscle invasive bladder cancer recurrence rate
Secondary Outcomes
- Progression(1 year)
Investigators
Mehmet Caglar Cakici
Department of Urology
Istanbul Medeniyet University